Michael E Klepser1. 1. Ferris State University, Big Rapids, and Borgess Medical Center, Kalamazoo, Michigan, USA. michaelklepser@ferris.edu
Abstract
PURPOSE OF REVIEW: The purpose of this review is to summarize modern data pertaining to the use of aerosolized antimicrobials for the treatment of and prophylaxis against pulmonary infections. RECENT FINDINGS: Few recent publications have examined the safety and efficacy of nebulized antibiotics. Two well conducted trials have been published that describe the utility of tobramycin solution for inhalation among cystic fibrosis patients. A couple of good reviews have also been published that have summarized the use of aerosolized antibiotics in other patient populations. SUMMARY: Data regarding this topic are scarce. At this time, data support the use of aerosolized tobramycin solution for inhalation in cystic fibrosis patients infected or colonized by Pseudomonas aeruginosa. Apart from this situation, widespread aerosolized administration of other agents in cystic fibrosis and non-cystic fibrosis patient populations should not be advocated.
PURPOSE OF REVIEW: The purpose of this review is to summarize modern data pertaining to the use of aerosolized antimicrobials for the treatment of and prophylaxis against pulmonary infections. RECENT FINDINGS: Few recent publications have examined the safety and efficacy of nebulized antibiotics. Two well conducted trials have been published that describe the utility of tobramycin solution for inhalation among cystic fibrosispatients. A couple of good reviews have also been published that have summarized the use of aerosolized antibiotics in other patient populations. SUMMARY: Data regarding this topic are scarce. At this time, data support the use of aerosolized tobramycin solution for inhalation in cystic fibrosispatients infected or colonized by Pseudomonas aeruginosa. Apart from this situation, widespread aerosolized administration of other agents in cystic fibrosis and non-cystic fibrosispatient populations should not be advocated.
Authors: María José de Jesús Valle; Francisco González López; Alfonso Domínguez-Gil Hurlé; Amparo Sánchez Navarro Journal: Antimicrob Agents Chemother Date: 2007-08-06 Impact factor: 5.191
Authors: Charles-Edouard Luyt; Marc Clavel; Kalpalatha Guntupalli; Jay Johannigman; John I Kennedy; Christopher Wood; Kevin Corkery; Dennis Gribben; Jean Chastre Journal: Crit Care Date: 2009-12-10 Impact factor: 9.097